Abemaciclib plus endocrine therapy in HR-positive, HER2-negative high-risk early breast cancer: efficacy in nodal subgroups. (PubMed, ESMO Open) - Oct 1, 2026 - "The similar recurrence risk for patients in the N1 high-risk and N2 subgroups, and consistent efficacy across nodal subgroups, support addition of 2 years of adjuvant abemaciclib to ET to improve outcomes in patients meeting monarchE cohort 1 N1 high-risk, N2, or N3 criteria."
Journal • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • HER-2
|
|
A Chan; B R Grimes; H Kalofonos; H M Nielsen; H S Rugo; J Cortes; J Sohn; K M Vianna; M H Abreu; M Martín; M P Goetz; M Zaiss; O Ozyilkan; P Neven; S Amdur; S M Tolaney; S Morales; S R D Johnston
|